Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program
Novartis has announced initial results of a large-scale vaccination campaign with Bexsero® to help protect against meningitis B within the Saguenay-Lac-Saint-Jean region of Québec, Canada. Bexsero is approved in 34 countries, including the European Union, Australia and Canada.
July 29, 2014